CCR7 Antibody (3D12) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-43332

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP1-43332-25ug
NBP1-43332-0.1mg
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Human

Applications

Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Paraffin

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2a Kappa Clone # 3D12

Format

BSA Free

Concentration

0.5 mg/ml

View all CCR7 Antibodies »

Product Specifications

Immunogen

The immunogen for this antibody was CCR7.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2a Kappa

Scientific Data Images for CCR7 Antibody (3D12) - BSA Free

Flow Cytometry: CCR7 Antibody (3D12) - BSA Free [NBP1-43332]

Flow Cytometry: CCR7 Antibody (3D12) - BSA Free [NBP1-43332]

Flow Cytometry: CCR7 Antibody (3D12) [NBP1-43332] - Analysis using the PE conjugate of NBP1-43332. Analysis of human peripheral blood cells using CCR7 PE conjugate. This can be used at less than or equal to 0.5 ug per test. Cell number should be determined empirically but can range from 10^5to 10^8 cells/test.
Flow Cytometry: CCR7 Antibody (3D12) - BSA Free [NBP1-43332]

Flow Cytometry: CCR7 Antibody (3D12) - BSA Free [NBP1-43332]

Flow Cytometry: CCR7 Antibody (3D12) [NBP1-43332] - Analysis using the Allophycocyanin conjugate of NBP1-43332. Staining of normal human peripheral blood cells with Anti-Human CD45RA FITC and Rat IgG2a ? Isotype Control APC (left) or Anti-Human CD197 (CCR7) APC (right).
Flow Cytometry: CCR7 Antibody (3D12) - BSA Free [NBP1-43332]

Flow Cytometry: CCR7 Antibody (3D12) - BSA Free [NBP1-43332]

Flow Cytometry: CCR7 Antibody (3D12) [NBP1-43332] - Analysis using the Biotin conjugate of NBP1-43332. Staining of normal human peripheral blood cells with Anti-Human CD45RA FITC and 1.0 micrograms of Rat IgG2a k Isotype Control Biotin (left) or 1.0 micrograms of Anti-Human CD197 (CCR7) Biotin (right) followed by Streptavidin PE. Cells in the lymphocyte gate were used for analysis.

Applications for CCR7 Antibody (3D12) - BSA Free

Application
Recommended Usage

Flow Cytometry

< = 0.5 ug /10^6 cells in 100 ul

Immunohistochemistry

1:10-1:500

Immunohistochemistry-Paraffin

1:10-1:500
Application Notes
This 3D12 antibody has been tested by flow cytometric analysis of human peripheral blood cells. This can be used at less than or equal to 0.5 ug per test. Cell number should be determined empirically but can range from 10^5to 10^8cells/test. It is recommended that the staining incubation time be increased to at least 45 minutes at 4°C for optimal staining.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS (pH 7.2)

Format

BSA Free

Preservative

0.09% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: CCR7

Chemokine receptor 7 (CCR7) is a G-protein coupled receptor (GPCR) that binds chemokine ligand 19 (CCL19) and chemokine ligand 21 (CCL21) and, together, this receptor-ligand interaction functions in inflammatory and adaptive immune response (1,2). The CCR7 protein contains 7-transmembrane spanning alpha helices and is 378 amino acids (aa) in length, with a theoretical molecular weight of 42.8 kDa (3,4). CCR7 is expressed on several cells within the immune system, including naive T cells, central memory T cells, regulatory T cells, naive B cells, a subset of double negative and single positive thymocytes, and mature dendritic cells (DCs) (1, 3).

The primary role of the CCR7/CCL19/CCL21 chemokine signaling axis is homing T cells and DCs to lymph nodes and lymphoid tissues to initiate an immune response (1,2,5,6). In the context of cancer, the CCR7 signaling axis appears to have two opposing roles (2). Downregulation of CCR7 on CD8+ T cells contributes to effector cell migration and anti-cancer activities via cytotoxic tumor-infiltrating lymphocytes (2). However, upregulation of CCR7 by cancer cells can result in cancer cell migration and metastasis (2). Overexpression of CCR7 has been implicated in a variety of cancers including breast, cervical, gastric, head and neck cell carcinoma, and prostate (1,2,7). Studies in breast cancer have found that hypoxia increases CCR7 expression, and this activation can affect cancer cell invasion, extravasation, proliferation, angiogenesis, and metastasis through induction of multiple signaling transduction pathways such as PI3K/AKT, MAPK, and JAK/STAT (5,7).

Given its important role in inflammation and immune response, several strategies have been employed to target the CCR7 signaling axis for cancer immunotherapy (2). Some cancer immunotherapies under investigation include intra-tumoral administration of CCL19 and CCL21, introduction of patient-derived cells transfected to express CCR7 or its ligands, and vaccines (2). Further interrogation of CCR7/CCL19/CCL21 signaling axis is required to develop better therapeutic strategies for cancer treatment.

References:

1. Comerford, I., Harata-Lee, Y., Bunting, M. D., Gregor, C., Kara, E. E., & McColl, S. R. (2013). A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine & growth factor reviews, 24(3), 269-283. https://doi.org/10.1016/j.cytogfr.2013.03.001

2. Salem, A., Alotaibi, M., Mroueh, R., Basheer, H. A., & Afarinkia, K. (2021). CCR7 as a therapeutic target in Cancer. Biochimica et biophysica acta. Reviews on cancer, 1875(1), 188499. https://doi.org/10.1016/j.bbcan.2020.188499

3. Yan, Y., Chen, R., Wang, X., Hu, K., Huang, L., Lu, M., & Hu, Q. (2019). CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention. Frontiers in cell and developmental biology, 7, 212. https://doi.org/10.3389/fcell.2019.00212

4. Uniprot (P32248)

5. Korbecki, J., Grochans, S., Gutowska, I., Barczak, K., & Baranowska-Bosiacka, I. (2020). CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. International journal of molecular sciences, 21(20), 7619. https://doi.org/10.3390/ijms21207619

6. Sanchez-Sanchez, N., Riol-Blanco, L., & Rodriguez-Fernandez, J. L. (2006). The multiple personalities of the chemokine receptor CCR7 in dendritic cells. Journal of immunology (Baltimore, Md. : 1950), 176(9), 5153-5159. https://doi.org/10.4049/jimmunol.176.9.5153

7. Rizeq, B., & Malki, M. I. (2020). The Role of CCL21/CCR7 Chemokine Axis in Breast Cancer Progression. Cancers, 12(4), 1036. https://doi.org/10.3390/cancers12041036

Alternate Names

BLR2, CC-CKR-7, CCR7, CD197, CDw197, CMKBR7, EBI1

Gene Symbol

CCR7

Additional CCR7 Products

Product Documents for CCR7 Antibody (3D12) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CCR7 Antibody (3D12) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.